Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
Cost of Revenue
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
|
Cost of Revenue
-¥4.6B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-1%
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Cost of Revenue
-¥1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Cost of Revenue
-¥5.7B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-24%
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Cost of Revenue
-¥3.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-11%
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Cost of Revenue
-¥28.9B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-9%
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Cost of Revenue
-¥242.3m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's Cost of Revenue?
Cost of Revenue
-4.6B
CNY
Based on the financial report for Mar 31, 2024, Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's Cost of Revenue amounts to -4.6B CNY.
What is Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-1%
Over the last year, the Cost of Revenue growth was 8%. The average annual Cost of Revenue growth rates for Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd have been -3% over the past three years , -3% over the past five years , and -1% over the past ten years .